 SAN DIEGO, Jan. 20, 2022 PRNewswire -- Cardiff Oncology, Inc. Nasdaq: CRDF, a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that company management will present and participate in one-on-one meetings at the B. Riley Securities 2022 Oncology Conference, taking place virtually January 27 28, 2022. 